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Recent theories propose that both GABA and glutamate signaling are compromised in patients with schizophrenia. These deficits can be
observed in several brain regions including the prefrontal cortex (PFC), an area extensively linked to the cognitive dysfunction in this
disease and notably affected by NMDA receptor antagonists such as phencyclidine (PCP). We have previously demonstrated that
inhibition of the nitric oxide (NO) pathways in the brain, particularly in the PFC, prevents a wide range of PCP-induced behavioral deficits
including disruption of prepulse inhibition (PPI). This study investigated the role of GABAB receptor signaling and NO in the effects of
PCP on PPI. Mice received systemic or prefrontal injections of the GABAB receptor agonist baclofen (2.5–5mg/kg and 1mM) before PCP
treatment (5mg/kg) and were thereafter tested for PPI. GABA/NO interactions were studied by combining baclofen and the NO
synthase inhibitor L-NAME (20mg/kg) in subthreshold doses. The role of GABAB receptors for NO production in vivo was assessed
using NO-sensors implanted into the rat PFC. PCP-induced PPI deficits were attenuated in an additive manner by systemic baclofen
treatment, whereas prefrontal microinjections of baclofen completely blocked the effects of PCP, without affecting PPI per se. The
combination of baclofen and L-NAME was more effective in preventing the effects of PCP than any compound by itself. Additionally,
baclofen decreased NO release in the PFC in a dose-related manner. This study proposes a role for GABAB receptor signaling in the
effects of PCP, with altered NO levels as a downstream consequence. Thus, prefrontal NO signaling mirrors an altered level of cortical
inhibition that may be of importance for information processing deficits in schizophrenia.
Neuropsychopharmacology (2009) 34, 1673–1684; doi:10.1038/npp.2008.225; published online 14 January 2009
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INTRODUCTION
Inhibitory neurotransmission appears to be impaired in
patients with schizophrenia as evidenced by the large
number of clinical studies implicating deficits in the GABA
system. These deficits range from reduced amounts of
mRNA coding both for the main GABA-generating enzyme,
glutamic acid decarboxylase (GAD67) and the GABA
membrane transporter GAT-1 (for review see Hashimoto
et al, 2008), to lowered levels of GABA (Cross et al, 1979;
Perry et al, 1979) and a modestly decreased density of
GABAergic interneurons (Benes et al, 1991, 2001). In
addition, signs of such a hypofunction have been observed
in many brain regions including areas that are considered
central to the pathophysiology of schizophrenia such as the
hippocampus (Benes, 1999), the anterior cingulate cortex
(Woo et al, 2004) and the prefrontal cortex (PFC) (Akbarian
et al, 1995; Hashimoto et al, 2003).
In parallel, excitatory glutamate receptors have been
implicated in the pathophysiology of schizophrenia. This is
based both on post-mortem studies showing changes in
binding, transcription, and subunit expression of these
receptors, and on altered levels of glutamate-related amino
acids such as N-acetylaspartate and N-acetylaspartylgluta-
mate (for review see Lewis and Moghaddam, 2006). In
addition, noncompetitive NMDA receptor antagonists such
as phencyclidine (PCP) induce behavioral changes in
humans that resemble positive symptoms, negative symp-
toms, and cognitive deficits in schizophrenia (Freedman
et al, 1987; Javitt and Zukin, 1991; Luby et al, 1959;
Yesavage and Freman, 1978). The strategy of modeling
aspects of schizophrenia in laboratory animals, by admin-
istration of noncompetitive NMDA antagonists such as PCP,
MK-801, or ketamine has proven effective in mimicking
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certain features of schizophrenia including disrupted work-
ing memory (Jentsch et al, 1997; Wass et al, 2006b) and
impaired preattentive information processing as measured
by prepulse inhibition of the acoustic startle (PPI; Fejgin
et al, 2007; Klamer et al, 2001; Linn et al, 2003; Mansbach
and Geyer, 1989). In the light of this, NMDA receptor
hypofunction has been suggested as a potential mechanism
underlying certain aspects of schizophrenia.
Interestingly, both clinical and animal studies show that
administration of NMDA antagonists produces signs of an
increase, rather than an expected decrease, in cortical
activity (Breier et al, 1997; Gozzi et al, 2008; Jackson et al,
2004; Lahti et al, 1995; Moghaddam et al, 1997). These
findings have led to the proposition that NMDA receptors
situated on GABAergic interneurons may be affected by this
class of psychotomimetic substances (Homayoun and
Moghaddam, 2007). NMDA channels are known to be
especially important for interneuron activity (Grunze et al,
1996; Jones and Buhl, 1993) and a recent study of PFC
function shows that inhibition of NMDA receptors prefer-
entially decreases the activity of fast-spiking interneurons,
thereby causing a disinhibition of pyramidal cells (Ho-
mayoun and Moghaddam, 2007). In line with this, a recent
publication by Behrens et al showed that the noncompeti-
tive NMDA receptor antagonist, ketamine, induces a
dysfunction of cortical interneurons that can be rescued
by a GABAA agonist (Behrens et al, 2007) and several
studies have demonstrated deleterious effects of NMDA
receptor antagonists on interneuron integrity and function.
Taken together, this points to a possible interaction where
glutamatergic output is disinhibited and subsequently
increased as a consequence of a disrupted GABA system
(for review see Lisman et al, 2008).
We have previously shown that the signaling molecule
nitric oxide (NO) is important for the ability of PCP to
induce schizophrenia-like behavior in rodents ranging from
PPI to working memory (Klamer et al, 2004, 2005a; Palsson
et al, 2007; Wass et al, 2006a, 2008). More specifically, an
NO/cGMP signaling mechanism in the medial PFC appears
to be important for these effects as cGMP, the main effector
of NO signaling, is increased in this region following PCP
treatment and normalized by pretreatment with a NO
synthase (NOS) inhibitor. Furthermore, prefrontal micro-
injections with an inhibitor of cGMP synthesis blocked the
effects of PCP on PPI (Fejgin et al, 2008). These findings
indicate that elevated levels of NO in the PFC may be
important for the effects of PCP. A possible explanation for
such an increase in NO production following NMDA
receptor antagonist treatment, could be a higher prefrontal
glutamate efflux caused by inhibition of interneuron output
followed by a subsequent disinhibition of glutamate release.
Tentatively, this increase in glutamate levels may activate
non-NMDA glutamate receptors and thereby induce NO
release. Notably, NO-producing cells in the rodent medial
PFC, hippocampus, and the primate frontal cortex also
synthesize GABA (Gabbott and Bacon, 1995; Szabadits et al,
2007; Yan et al, 1996), indicating a close relationship
between NO and GABA signaling. The GABAB agonist
baclofen has been shown to block the PPI deficits induced
by the NMDA receptor antagonist MK-801 in both mice and
rats, and also to improve spontaneous PPI deficits in DBA/
2J mice (Arai et al, 2008; Bortolato et al, 2004, 2007). These
findings demonstrate that GABAB signaling is important for
the regulation of PPI and that the acute effects of NMDA
antagonists may be mediated by disruption of interneuron
function.
The aim of this study was to investigate the importance of
GABAB and NO signaling, particularly in the PFC, for the
disruptive effects of PCP on preattentive information
processing. To this end, mice received both systemic and
prefrontal injections of the GABAB receptor agonist
baclofen before PCP treatment and were thereafter tested
for PPI. To study GABA/NO interactions in relation to PPI,
a combination of baclofen and the NOS inhibitor L-NAME
were administered in doses not sufficient to block the
effects of PCP per se. Finally, the regulatory role of GABAB
receptors for NO production was assessed in vivo using
novel, microelectrochemical NO-sensors implanted into the
rat medial PFC.
METHODS
Animals
Male NMRI mice (Charles River, Germany or B&K, Sweden;
25–35 g) and male Sprague–Dawley rats (Taconic, Denmark;
290–400 g) were used in this study. The animals were
housed nine per cage (mice) or four (rats) per cage, in a
colony room under constant temperature (20±11C) and
humidity (50±5%). Animals were allowed to acclimatize
for at least 1 week before surgery or behavioral testing. The
daylight cycle was maintained artificially (lights on from
0600 to 1800 hours) and behavioral experiments and
biochemical measurements were conducted during the light
phase. The Ethics Committee for Animal Experiments,
Go¨teborg, Sweden, approved all experimental procedures
used in this study.
Drugs
Phencyclidine hydrochloride (Sigma Chemicals, St Louis,
MO, USA), R-baclofen (more active enantiomer; Sigma-
Aldrich, Germany) and NG-nitro-L-arginine methyl ester (L-
NAME; Sigma-Aldrich) were used in this study. All drugs
for systemic injections were dissolved in saline (0.9% NaCl)
and administered either intraperitoneally (i.p., mice) or
subcutaneously (s.c., rats). Mice were always injected a
volume of 10 ml/kg and rats 2 ml/kg. For local injections, R-
baclofen was dissolved in Ringer’s solution. The doses were
chosen for optimal disruption of PPI (PCP 5 mg/kg) and
below the threshold for reversing these deficits (L-NAME)
based on previously published studies (Klamer et al, 2001).
Baclofen doses were based on PPI studies in mice (Arai
et al, 2008; Bortolato et al, 2007) and rats (Bortolato et al,
2004).
Surgical Procedure
Local injection experiments. The mice were anesthetized
with isoflurane (Isofluran Baxter; Apoteket AB, Sweden),
placed in a Kopf stereotaxic instrument (David Kopf
Instruments, Tujunga, CA, USA), and kept on a heating
pad to prevent hypothermia and administered ketoprofen
(Romefen, Veter, Sweden) to reduce postoperative pain. The
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skull was then exposed, and two holes for the guide
cannulas (stainless steel, length 10 mm, with an o.d./i.d. of
0.6/0.45 mm), and one hole for an anchor screw were
drilled. The coordinates used for the medial PFC region
relative to the bregma were as follows: anterior + 1.8 mm,
lateral to midline ±0.8 mm, and ventral 1.0 mm from the
brain surface (Franklin and Paxinos, 1996). The dura was
removed using a sharp needle, and the guide cannulas and
the anchor screw were secured with dental cement
(Dentalon plus; AgnTho’s AB, Lidingo¨, Sweden). After
surgery the mice were administered 1 ml of saline (s.c.) to
prevent dehydration and allowed to recover for 3–4 days
while housed individually in standard plastic cages.
NO measurements. The rats were anesthetized with
isoflurane, placed in a Kopf stereotaxic instrument and
kept on a heating pad to prevent hypothermia. An incision
was placed down the midline of the skull and the bone was
exposed. Four holes for the anchor screws, two holes for the
reference (8T Ag wire, 200-mm bare diameter; Advent
Research Materials, UK) and auxiliary (8T Ag wire)
electrodes, and one hole for the sensor electrode was
drilled. Electrodes were then implanted following a
previously described procedure (Lowry et al, 1997). The
coordinates used for the medial PFC relative to bregma were
as follows: anterior + 3.2 mm, lateral to midline±0.8 mm,
and ventral 4.2 mm from the brain surface. The electrode
was inserted into the brain and connected to a pedestal that
was secured to the anchor screws with dental cement.
Sensor placement was balanced between the left and right
hemispheres throughout the experiment. During surgery,
the rats were administered 2.0 ml of saline (s.c.), to reduce
postoperative dehydration and an analgesic (carprofen) to
reduce postoperative pain. The animals were allowed to
recover for 2–4 days before commencing experiments. They
were housed individually in standard plastic cages.
Probe and injection placement verification. After termina-
tion of the local injection and voltammetry experiments the
mice and rats were decapitated. The brains were removed
and frozen at 801C. Injection or sensor placement was
verified by sectioning the brains using a cryostat and an
atlas of the mouse or rat brain for reference (Figure 1;
Franklin and Paxinos, 1996; Paxinos and Watson, 2005).
Prepulse Inhibition
Apparatus. Acoustic startle was recorded using a MOPS 3
startle response recording system (Metod och Produkt
Svenska AB, Sweden). The animals were placed in small
plexiglass cages (10 5.5 6 cm3) that were suspended at
the top to a piston. A movement of the animal in the cage
caused a displacement of the piston, the acceleration of
which was registered by a piezoelectric accelerometer. This
signal was sampled and digitized by a microcomputer that
also controlled the delivery of acoustic stimuli. Startle
amplitude was defined as the maximum signal amplitude
occurring 8–30 ms after the startle-eliciting stimulus. Four
cages were used simultaneously and each cage was housed
in a dimly lit and sound-attenuated cabinet
(52 42 38 cm3). The cages were calibrated for equal
sensitivity before testing and a mouse was always tested in
the same cage at subsequent tests. The acoustic stimuli
consisted of white noise, which was delivered by two high-
frequency loudspeakers built into the ceiling of the cabinet.
PPI paradigm. Each test session started with an 8-min
adaptation period containing only white background noise
at 62 dB(A). Startle pulse was set to 105 dB(A) and prepulse
intensities to 9, 12, and 15 dB(A) above background.
Duration of acoustic stimuli was set to 20 ms for both
prepulses and startle pulses and interstimulus interval (ISI)
was set to 40 ms. The prepulse and pulse were discrete, and
separated by the ISI. After the adaptation period, the
animals were subjected to a series of five startle pulse-alone
trials that were omitted from the analysis because they only
served to accommodate the animals to the sudden stimulus
onset. The animals were then subjected to a pseudorando-
mized combination of 3 prepulse-alone trials for each
prepulse intensity, 45 pulse-alone trials, and 15 prepulse +
pulse trials for each prepulse intensity. Trials were
separated by 5–15 s intervals and all these intervals included
a measurement of intertrial activity. This served as a general
marker of basal animal activity (not stimulus evoked)
throughout the experiment. The full PPI test lasted
approximately 24 min including the adaptation period.
Figure 1 Coronal rat brain section of the medial PFC (AP + 3.24mm
from bregma) showing actual sensor placement. Each black circle
represents the tip placement of one electrode (n¼ 7). Reprinted from
The Rat Brain in Stereotaxic Coordinates (Paxinos and Watson, 2005) with
permission from Elsevier.
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Electrochemical Detection of Nitric Oxide
Prefrontal cortex NO levels were determined using a NO
selective amperometric microsensor. The microsensor is a
Nafions-modified Pt disk electrode (patent no. S2007/
00774). The sensor design has been validated for in vitro
and in vivo NO sensitivity (Brown et al, 2005; Finnerty,
2008) and in vitro selectivity against ascorbic acid, uric acid,
and dopamine (Brown and Lowry, 2003). The NO oxidation
current (electrode potential of + 0.90 V against an Ag
reference electrode) was detected using a low-noise
potentiostat (Biostat II; Electrochemical and Medical
Systems, UK) and converted using an A/D converter
(PowerLab; ADInstruments, United Kingdom). The digital
signal was then recorded using Chart software (v5;
ADInstruments) running on a PC. Each animal was
connected to the in vivo voltammetry equipment on the
day before an experiment to allow the NO oxidation current
to reach a stable baseline. All experiments were carried out
with the animal in its home cage. Rats were chosen for this
experiment because the characterization of sensors has been
carried out on this species and due to limitations regarding
the size of the equipment.
Experimental Layout
All mice used for PPI testing were subjected to a pretest
before surgery and/or drug treatment to ensure that they
expressed basal startle reactivity.
Experiment 1: baclofen 2.5mg/kg. Each animal (n¼ 16)
received all the four treatment combinations (sal + sal,
baclofen + sal, sal + PCP, and baclofen + PCP) in a balanced
crossover design. Each test was separated by a 3- to 4-day
long washout period. Mice were first pretreated with
baclofen at a dose of 2.5 mg/kg or saline and 53 min, later
they received the second injection consisting of PCP (5 mg/
kg) or saline. Seven minutes after the last injection the
animals were placed in the startle cages for the adaptation
period and subsequent PPI test.
Experiment 2: baclofen 5mg/kg. The mice (n¼ 16) were
treated exactly as in the above experiment, but with a
baclofen dose of 5 mg/kg.
Experiment 3: local injection of baclofen into the medial
prefrontal cortex. At the day of the experiment a dummy
cannula was inserted and retracted from the cannula
guides to reduce the risk of spreading depression. After
this, the animals (n¼ 31) were allowed to rest for 60 min
before a first PPI test. Based on the results of this test the
animals were divided into four treatment groups with
comparable basal PPI and startle reactivity: veh + sal
(n¼ 8); baclofen + sal (n¼ 8); veh + PCP (n¼ 7), and
baclofen + PCP (n¼ 9). The mice then received a bilateral
injection of either 1 ml baclofen or vehicle (Ringer’s
solution) 1.6 mm below the brain surface. The local
injection lasted 1 min and the cannula was left in place for
another 45 s to allow diffusion of the drug. Immediately
after the local injection the animals were administered PCP
(5 mg/kg) or saline systemically and 7 min later they were
placed in the startle chambers for the second PPI test.
Experiment 4: low dose of L-NAME. As above, the
experiment used a balanced crossover design with a 3- to
4-day long washout period. Each animal (n¼ 16) received
all the four treatment combinations (sal + sal, L-NAME +
sal, sal + PCP, and L-NAME + PCP). Pretreatment with a
subthreshold dose of L-NAME (20 mg/kg) preceded the PCP
injection (5 mg/kg) by 10 min. Seven minutes later, the mice
were placed in the startle cages.
Experiment 5: baclofen 2.5mg/kg in combination with low
dose of L-NAME. To examine the putative interactions
between GABA and NO signaling in the brain mice (n¼ 16)
were pretreated with a low dose of baclofen (2.5 mg/kg) in
combination with a subthreshold dose of L-NAME (20 mg/
kg). Each mouse received all of the following four treatment
combinations separated by a 3- to 4-day washout period: sal
+ sal + sal; baclofen + L-NAME + sal; sal + sal + PCP; and
baclofen + L-NAME + PCP. These injections were identical
in timing to the earlier systemic experiments using these
compounds and thus also followed by a PCP injection 7 min
before the beginning of the PPI test.
Experiment 6: NO measurements following dose response
with baclofen. Each rat was subjected to four drug
treatments with a 2-day washout period between each
treatment. The drug treatments consisted of saline and
baclofen at a dose of 2.5, 5, and 10 mg/kg (s.c.) and the
doses were based on previous studies on baclofen and PPI
in the rat (Bortolato et al, 2004). The order of the drug
combinations was varied between animals in a balanced
manner.
Data and Statistical Analysis
PPI. The mean response amplitude for pulse-alone trials (P)
was calculated for each mouse and test. This measure was
used in the statistical analysis to assess drug-induced
changes in acoustic startle response. The mean response
amplitude for prepulse-pulse trials (PP) was also calculated
and used to express the percent prepulse inhibition
according to the following formula:
Prepulse inhibition ð%Þ ¼ 100  ½ðPP=PÞ100
Using this formula, a 0% value denotes no difference
between pulse-alone and prepulse-pulse response ampli-
tudes and consequently no PPI. Statistical analysis for
systemic experiments was performed using a three-way
repeated measures ANOVA with pretreatment (baclofen, L-
NAME, or sal), treatment (PCP or sal), and prepulse
intensity (9, 12, and 15 dB) as within subject factors.
Statistical analysis of the local injection experiments was
conducted using a three-way mixed model ANOVA with
pretreatment (baclofen or veh) and treatment (PCP or sal)
as between-subject factors and prepulse intensity as within-
subject factor. There was a significant main effect of
prepulse intensity in each PPI experiment (data not shown).
As no prepulse intensity pretreatment treatment inter-
action effect could be demonstrated in any of the datasets,
PPI data was collapsed across prepulse intensities and
presented as an average % PPI. Acoustic startle response
(ASR) and intertrial activity (ITA) were analyzed using a
two-way repeated measures or mixed model ANOVA with
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pretreatment and treatment as within- or between-subject
factors depending on experiment type. Given the a priori
hypothesis that baclofen and L-NAME would interfere with
the effects of PPI, specific differences between treatment
groups were evaluated in all experiments by Bonferroni’s
post hoc tests. Two-tailed levels of significance were used
and po0.05 was considered statistically significant.
NO measurements. The current over time (sampling rate 4/s)
recorded in Chart was used as data. The mean of an
approximately 5-min long sampling period just before drug
treatment was used as baseline. The mean current change
from baseline was calculated for a 5-min sampling period
surrounding the time points of 30, 60, and 90 min after
injection. This time frame was chosen to facilitate
comparison with experiments 1–5 and previously published
behavioral studies (Johansson et al, 1997; Klamer et al,
2005b; Wass et al, 2006a). To investigate whether the drug
treatments had any significant effect on NO levels, a two-
way repeated measures ANOVA with treatment and time
point as within subject factors was used. In the presence of
an interaction effect, his was followed by a one-way
repeated measures ANOVA for each time point and where
appropriate a Bonferroni’s post hoc tests was performed for
comparisons between groups. Two tailed levels of signifi-
cance were used and po0.05 was considered statistically
significant.
RESULTS
Experiment 1: Baclofen 2.5mg/kg does not Interfere
with the Effects of PCP on PPI
Statistical analysis of PPI showed a significant effect of PCP
(5 mg/kg) treatment (effect of treatment, F(1,15)¼ 25.83,
po0.001) but not of pretreatment with baclofen (2.5 mg/kg).
No pretreatment treatment interaction effect could be
demonstrated, suggesting that baclofen did not block the
effects of PCP on PPI at this dose (Figure 2a). Post hoc
comparisons showed that the baclofen + sal group did not
differ from controls whereas PCP-treated animals showed a
significantly lower PPI compared to the controls (po0.05).
As already indicated by the lack of interaction, this effect
was not prevented by pretreatment with baclofen because
the PPI of the baclofen + PCP group was significantly lower
than that of the control group (po0.05) but not different
from the veh + PCP group.
There was no effect of drug treatment on ASR in
experiment 1 (Table 1). Basal activity levels, as measured
by ITA (Figure 3a), were significantly increased in PCP-
treated animals (effect of treatment, F(1,15)¼ 47.77,
po0.001) and decreased in baclofen-treated animals (effect
of pretreatment, F(1,15)¼ 5.505, po0.05). Pretreatment with
baclofen partially blocked the PCP-induced hyperactivity as
evidenced by a significant pretreatment treatment inter-
action (interaction effect, F(1,15)¼ 5.985, po0.05). This was
further supported by post hoc comparisons showing higher
ITA in PCP-treated animals compared to controls
(po0.001) whereas this could not be demonstrated for the
baclofen + PCP group. However, the baclofen + PCP group
did not show a significantly lower ITA than the PCP group,
suggesting that the blockade was only partial.
Experiment 2: Baclofen 5mg/kg Elevates Basal PPI and
Prevents the Effects of PCP
PCP (5 mg/kg) had a main disruptive effect on PPI (effect
of treatment, F(1,15)¼ 74.02, po0.001) whereas baclofen
(5 mg/kg) increased PPI significantly (effect of pretreat-
ment, F(1,15)¼ 45.01, po0.001; Figure 2b). Similar to the
lower dose of baclofen, no pretreatment treatment inter-
action effect could be observed, suggesting additive effects
of baclofen and PCP. Post hoc comparisons revealed an
increased PPI in the baclofen + sal group compared to
Figure 2 The effects of pretreatment with baclofen (BAC) and/or NG-nitro-L-arginine methyl ester (L-NAME) on PCP-induced disruption of prepulse
inhibition (PPI) in mice. Data are presented as mean PPI values collapsed over prepulse intensities±SEM for each treatment group. (%po0.05,%%po0.01,
%%%po0.001 vs control group; #po0.05 vs PCP group; Bonferroni’s test). (a) A low dose of BAC (2.5mg/kg) does not interfere with the effects of PCP
(5mg/kg) on PPI. (b) A high dose of BAC (5mg/kg) attenuates the effects of PCP in an additive manner. (c) Pretreatment with a subthreshold dose of
L-NAME (20mg/kg) does not interfere with the effects of PCP on PPI. (d) Combination of BAC (2.5mg/kg) and L-NAME (20mg/kg) increases basal PPI and
attenuates the effects of PCP on PPI in an additive manner.
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controls (po0.01), suggesting an increasing effect of this
dose of baclofen on PPI per se. PCP-treated animals had a
lower PPI compared to controls (po0.001) and had also
significantly lower PPI than the baclofen + PCP group
(po0.01). Furthermore, baclofen + PCP-treated animals
did not differ significantly from controls, indicating a
normalization of PCP-induced PPI deficits by pretreatment
with baclofen.
Statistical analysis of ASR (Table 1) showed that baclofen
significantly lowered this measure (effect of pretreatment,
F(1,15)¼ 37.80, po0.001) whereas no main effect of PCP
treatment could be demonstrated. Post hoc comparisons
showed that both the baclofen + sal group and the baclofen
+ PCP group had significantly lower ASR than controls
(po0.001 for both comparisons). Analysis of ITA showed a
similar pattern to experiment 1 (Figure 3b). ITA was
increased by PCP (effect of treatment, F(1,15)¼ 29.57,
po0.001), decreased by baclofen (effect of pretreatment,
F(1,15)¼ 31.44, po0.001), and a significant pretreatment
treatment interaction could be demonstrated (interaction
effect, F(1,15)¼ 23.18, po0.001). Post hoc comparisons
showed a lower ITA in baclofen-treated mice compared to
controls (po0.05). PCP-treated animals had a higher ITA
than both controls (po0.001) and baclofen + PCP-treated
animals (po0.001) suggesting a normalization of activity
levels by baclofen. This was further supported by an
absence of difference between the baclofen + PCP group
and controls.
Experiment 3: Prefrontal Injection of Baclofen Blocks
PCP-Induced PPI Deficits
Systemic PCP (5 mg/kg) injection disrupted PPI (effect of
treatment, F(1,28)¼ 8.744, po0.01) whereas no main effect of
local pretreatment with baclofen (1 mM) could be shown
(Figure 4a). A significant pretreatment treatment interac-
tion effect indicated that prefrontal pretreatment with
baclofen blocked the PPI deficits induced by systemic PCP
administration (interaction effect, F(1,28)¼ 5.597, po0.05).
Post hoc analysis further supported this interpretation as
PCP-treated animals had lower PPI than both controls
(po0.01) and baclofen + PCP-treated animals (po0.05). In
addition, the PPI of the baclofen + PCP group did not differ
Table 1 Acoustic Startle Response (ASR) After Different Treatment Combinations in Experiments 1–5
Exp 1 Exp 2 Exp 3 Exp 4 Exp 5
VEH BAC 2.5 VEH BAC 5a VEH BAC 1mM VEH L-NAME VEH BAC+L-NAME
SAL 908±104 990±98.4 867±96.6 501±91.4b 505±155 801±202 812±120 729±108 1355±134 1141±147
PCP 821±90.7 847±85.2 791±89.7 420±62.2b 359±92.5 430±120 673±68.7 686±89.7 1190±95.0 1101±128
apo0.05 main effect of pretreatment following 3-way ANOVA.
bpo0.001 vs control group, Bonferroni’s test.
Data are presented as mean ASR values±SEM for each treatment group. Baclofen (BAC; 2.5–5mg/kg systemically or as bilateral microinjections 1mM), NG-nitro-L-
arginine methyl ester (L-NAME; 20mg/kg); and PCP (5mg/kg) were administered in five separate experiments. The high dose of baclofen decreased ASR in
experiment 2.
Figure 3 The effects of pretreatment with baclofen (BAC) and/or NG-nitro-L-arginine methyl ester (L-NAME) on PCP-induced hyperactivity in mice as
measured by intertrial activity (ITA). Data are presented as mean ITA values±SEM for each treatment group. (%po0.05,%%%po0.001 vs control group;
#po0.05, ##po0.01, ###po0.01 vs PCP group; Bonferroni’s test). (a) A low dose of BAC (2.5mg/kg) partially interferes with the effects of PCP (5mg/kg)
on ITA. (b) A high dose of BAC (5mg/kg) decreases ITA and blocks the PCP-induced hyperlocomotion. (c) Pretreatment with a subthreshold dose of
L-NAME (20mg/kg) partially attenuates the effects of PCP on ITA. (d) Combination of BAC (2.5mg/kg) and L-NAME (20mg/kg) blocks the PCP-induced
hyperactivity.
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from the control group, suggesting a full blockade of the
effects of PCP.
ASR was not affected by any treatment combination in
experiment 3 (Table 1). ITA levels were significantly
increased in PCP-treated animals (effect of treatment,
F(1,28)¼ 12.18, po0.01) and animals locally pretreated with
baclofen showed a decreased ITA (effect of pretreatment,
F(1,28)¼ 4.234, po0.05; Figure 4b). No pretreatment treat-
ment interaction effect was present. Post hoc comparisons
revealed a significantly increased ITA in the PCP group
(po0.01) compared with controls, but did not show a
difference between the baclofen + sal group and controls.
Furthermore, PCP-treated animals did not differ from the
baclofen + PCP group suggesting an inability of locally
administered baclofen to block PCP-induced hyperactivity.
However, the ITA of the baclofen + PCP group was not
different from that of the control group, which in the
absence of an interaction effect can be interpreted as a
tendency to attenuate the effects of PCP.
Experiment 4: Pretreatment with a Low Dose of L-NAME
does not Interfere with the Effects of PCP
L-NAME (20 mg/kg) administration did not produce a main
effect on PPI whereas PCP significantly decreased PPI
(effect of treatment, F(1,15)¼ 40.15, po0.001; Figure 2c). No
pretreatment treatment interaction effect could be de-
monstrated and post hoc comparisons did not show any
significant differences between the L-NAME + PCP group
and PCP-treated animals. Both PCP-treated animals and the
L-NAME + PCP group differed significantly from controls,
confirming that this dose of L-NAME did not attenuate the
effects of PCP on PPI.
ASR was not affected by any treatment combination in
experiment 4 (Table 1). Statistical analysis showed a
significant increase in ITA levels following PCP treatment
(effect of treatment, F(1,15)¼ 37.94, po0.001; Figure 3c) and
a significant effect following pretreatment with L-NAME
(effect of pretreatment, F(1,15)¼ 12.18, po0.001). Further-
more, a significant pretreatment treatment interaction
effect for ITA could be demonstrated (interaction effect,
F(1,15)¼ 6.220, po0.05). Post hoc comparisons of ITA levels
showed that PCP-treated animals had significantly higher
ITA levels than controls (po0.05). L-NAME + PCP-treated
animals had lower ITA levels than PCP-treated animals
(po0.05), but also showed a significant increase in ITA
compared to controls (po0.001) suggesting a partial
attenuation of the PCP-induced hyperactivity.
Experiment 5: Baclofen + L-NAME Combination
Increases Basal PPI and Prevents the Effects of PCP
Pretreatment with subthreshold doses of baclofen (2.5 mg/
kg) and L-NAME (20 mg/kg) significantly increased PPI
(effect of pretreatment, F(1,15)¼ 21.58, po0.001; Figure 2d).
As above, PCP-treatment decreased PPI levels (effect of
treatment, F(1,15)¼ 31.41, po0.001) but no pretreatment
treatment interaction was present, suggesting additive
effects of these two factors on PPI. Post hoc comparisons
confirmed that the combined pretreatment increased PPI in
an additive manner as the baclofen + L-NAME + sal group
had significantly higher PPI than controls (po0.01).
Additionally, the pretreatment appeared to prevent the
effects of PCP, as the baclofen + L-NAME + PCP group had
significantly higher PPI than PCP-treated animals (po0.05)
but did not differ from controls.
ASR was not affected by any treatment combination in
experiment 5 (Table 1). ITA was significantly increased after
PCP treatment (effect of treatment, F(1,15)¼ 29.26, po0.001)
and lowered after pretreatment with baclofen and L-NAME
(effect of pretreatment, F(1,15)¼ 12.22, po0.01; Figure 3d). A
significant pretreatment treatment interaction (interac-
tion effect, F(1,15)¼ 16.66, po0.001) suggested that the
combined pretreatment blocked the effects of PCP on ITA.
Post hoc analysis confirmed this as the significant increase
in ITA levels following PCP (po0.001) could not be seen for
the baclofen + L-NAME + PCP group whereas the latter
group had significantly lower ITA than PCP-treated animals
(po0.01).
Experiment 6: Baclofen Decreases NO Levels in the
mPFC
Baclofen treatment significantly decreased the NO current
over the sampling time (effect of treatment, F(3,18)¼ 4.233,
po0.05; Figure 5). Furthermore, this effect was time
dependent as evidenced by a treatment time point (30,
60, or 90 min) interaction effect (interaction effect,
F(6,36)¼ 2.772, po0.05). This warranted a detailed analysis
for each time point. Analysis of the change in NO current at
30 min revealed no significant effect of baclofen treatment.
At 60 min after injection, a main effect of baclofen could be
detected (effect of treatment, F(3,18)¼ 3.264, po0.05)
suggesting a decrease in NO current due to baclofen
treatment. However, post hoc comparisons did not reveal
Figure 4 The effects of bilateral baclofen treatment (BAC; 1mM) into
the medial PFC followed by systemic PCP administration (5mg/kg) on
prepulse inhibition (PPI) and intertrial activity (ITA). Data are presented as
mean PPI values collapsed over prepulse intensities±SEM for each
treatment group. (%%po0.01 vs control group; #po0.05 vs PCP group;
Bonferroni’s test). (a) Prefrontal pretreatment with BAC blocks PCP-
induced PPI disruption. (b) Prefrontal pretreatment with BAC partly blocks
PCP-induced hyperactivity.
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any significant difference between the control group and the
different treatment groups, indicating that this decrease was
relatively subtle. Finally, analysis of the change in NO
current 90 min after injection revealed a significant decrease
following baclofen treatment (effect of treatment,
F(3,18)¼ 5.118, po0.01). Post hoc comparisons showed that
baclofen 5 mg/kg (po0.05) significantly decreased NO
levels, whereas this was not the case for 2.5 mg/kg or the
10 mg/kg dose. This indicates a dose-related effect of
baclofen on NO levels in the medial PFC.
DISCUSSION
In this study, PCP-induced PPI deficits and hyperactivity
were attenuated by systemic pretreatment with the GABAB
agonist baclofen in a dose-related manner. Although
systemic baclofen normalized PPI in an additive manner,
prefrontal microinjections of baclofen completely blocked
the PPI-disruption caused by PCP, without affecting this
measure per se. Furthermore, the combination of baclofen
and an NOS inhibitor was more effective in preventing the
effects of PCP than any compound by itself. Additionally, in
vivo measurements of NO levels showed that baclofen
inhibited NO release in the PFC.
Effects of Baclofen
The finding that baclofen attenuates the disruptive effects of
PCP on PPI, extends previous studies showing that systemic
administration of this compound blocks the effects of the
NMDA receptor antagonist, dizocilpine (MK-801), in both
rats (Bortolato et al, 2004) and mice (Arai et al, 2008). In
addition, baclofen improves spontaneous PPI deficits in
DBA/2J mice without affecting basal PPI in control mice
(Bortolato et al, 2007). The above-mentioned studies have
all demonstrated effects in a dose range similar to this
study, although direct comparisons are somewhat compli-
cated by interstudy differences in mice strain, rodent
species, or baclofen enantiomer. One important difference
is that baclofen (5 mg/kg) increased basal PPI in this study
and thus attenuated the effects of PCP in an additive rather
than interactive manner. Although such an increase is at
variance with previous studies, the present findings point to
a role of GABAB receptors in the regulation of preattentive
information processing, possibly indicating that stimulation
of these receptors may have an antipsychotic effect in
patients. Early studies of the antipsychotic potential of
baclofen showed beneficial effects in patients with schizo-
phrenia (Frederiksen, 1975; Schopf and Hucker, 1977),
although these findings were not replicated in later studies
(Beckmann et al, 1977; Bigelow et al, 1977; Gulmann et al,
1976). In this study, the higher dose of baclofen (5 mg/kg)
significantly lowered startle reactivity, possibly due to the
muscle-relaxing properties of this compound. However, PPI
does not appear to be correlated to either drug-induced or
genotype-induced differences in ASR, suggesting that the
decrease in ASR was not likely confounding the PPI
measurements in experiment 2 (Klamer et al, 2005b; Paylor
and Crawley, 1997).
At the lower dose (2.5 mg/kg) baclofen also blocked the
hyperactivity caused by PCP as measured by ITA without
affecting this measure in itself, in analogy to an earlier study
in mice (Menon et al, 1980). A possible mechanism behind
this may be that baclofen stabilizes dopamine neuron firing
in the midbrain (Erhardt et al, 1998, 2002). In support of
this, baclofen has proven effective against the disruption of
PPI by metamphetamine (Arai et al, 2008), D-amphetamine-
induced hypermotility and disruption of successive dis-
crimination (Ahlenius et al, 1975; Phillis et al, 2001; Zhou
et al, 2004). Although the hyperactivity caused by common
psychotomimetics such as D-amphetamine, traditionally has
been attributed to stimulation of the mesocorticolimbic
dopamine system, this may not be true for NMDA receptor
antagonists such as PCP where the effects on locomotion are
temporally dissociated from changes in dopamine levels
(Adams and Moghaddam, 1998). The present finding that
prefrontal injections of baclofen partially block PCP-
induced hyperactivity may be an additional sign that also
changes in nondopaminergic cortical transmission should
be considered as a part of the explanation.
Regional Effects of Baclofen
Local injection of baclofen in the medial PFC effectively
blocked the PPI disruption caused by systemic PCP
administration without affecting this measure per se. The
apparent difference in the effects of systemic and prefrontal
administration of baclofen on baseline PPI may result from
the interference with GABA signaling at multiple brain
regions following systemic injection. PPI is known to be
modulated in a top-down manner by the PFC, and also by
brain nuclei more proximal to the primary startle circuit
Figure 5 Prefrontal NO release is decreased following systemic baclofen
administration. (a) A representative voltammogram showing the oxidation
current in the medial prefrontal cortex after saline or baclofen (5mg/kg,
t¼ 0) administration. Data are expressed as current (pA) over time
(seconds). (b) Change in prefrontal NO release 30, 60, and 90min after
systemic baclofen administration. Data are presented as mean change in
NO current compared to baseline±SEM for each treatment group
(%po0.05 vs control group, Bonferroni’s test).
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such as the lateral globus pallidus (LGP) and the
pedunculopontine nucleus (PPTg; Koch and Schnitzler,
1997; Kodsi and Swerdlow, 1997; Swerdlow et al, 2001).
Interestingly, it was recently shown that PPTg-targeting
GABAergic neurons in the LGP are activated at both
prepulse and prepulse + pulse (PPI) conditions, and that
transient inactivation of this region by lidocaine decreases
PPI in mice. Furthermore, infusions of both GABAA and
GABAB receptor antagonists into the PPTg decrease PPI,
suggesting that the LGP regulates PPI by acting on GABA
receptors in the PPTg (Diederich and Koch, 2005; Takahashi
et al, 2007). Thus, it is possible that systemic (but not
prefrontal) injections of baclofen used in this study, affects
PPTg in the opposite direction, thereby causing an increase
in basal PPI.
The present findings suggests that impairments in
prefrontal GABAB-mediated inhibition may be important
for the effects of PCP on information processing and that
restoration of inhibitory signaling through these receptors
is sufficient to normalize PPI. It is now known that NMDA
receptor antagonists stimulate cortical glutamate and
dopamine release (Adams and Moghaddam, 1998; Moghad-
dam et al, 1997) and suppress inhibitory synaptic transmis-
sion (Zhang et al, 2008). Interestingly, perfusion of baclofen
into the PFC has been demonstrated to decrease both basal
dopamine release and NO release in this region (Ishizuka
et al, 2000; Santiago et al, 1993) and also to block the
behavioral arousal and hyperlocomotion caused by the
NMDA receptor antagonist AP-5 (Feenstra et al, 2002).
Prefrontal injections of baclofen also inhibit stimulated
glutamate release in the ventral tegmental area, which
receives corticofugal projections from the PFC and conse-
quently reflects the degree of prefrontal excitation (Harte
and O’Connor, 2005). Thus, the present effects of baclofen
may be explained as a restoration of inhibitory function
followed by stabilization of aberrant glutamate release and/
or by an interaction with the dopamine and NO systems in
the PFC. Notably, GABAB receptor expression appears to be
reduced both in the PFC, entorhinal cortex, and hippo-
campus of subjects with schizophrenia, indicating that these
receptors may have an important role in the pathophysiol-
ogy of the disease (Ishikawa et al, 2005; Mizukami et al,
2000, 2002).
GABAB and Nitric Oxide
The combination of subthreshold doses of baclofen and
L-NAME was more effective in preventing the effects of PCP
than any compound by itself. However, the increasing effect
of pretreatment on PPI, in combination with the absence of
a pretreatment treatment interaction, suggests that this
effect mainly is of an additive nature. An important
observation is that neither baclofen nor L-NAME (at
subthreshold doses) increased basal PPI levels, whereas
this effect was evident for their combination. This finding
opens up the possibility of a connection between GABAB
receptors and NO release in the regulation of PPI. A similar
relationship between these two signaling systems has
previously been described in the hippocampus where basal
cGMP efflux is increased by local administration of GABAB
antagonists and decreased by baclofen (Fedele et al, 1997).
Future studies using local pretreatment with GABAB
antagonists in the PFC, may clarify whether the observed
normalizing effect of baclofen/L-NAME on disrupted PPI is
dependent on prefrontal GABAB receptor signaling.
In this study, systemic baclofen administration decreased
NO levels over time in the rat medial PFC, indicating that
cortical NO release may be under the influence of upstream
GABAB receptor signaling. It has been shown that release of
both glutamate and the effector of NO signaling, cGMP, are
decreased by baclofen but increased by GABAB antagonists
(Fedele et al, 1997; Harte and O’Connor, 2005; Waldmeier
et al, 2008). Consequently, antagonists of the GABAB
receptor may elevate NO levels, possibly through a
disinhibitory activation of glutamate receptors. A similar
disinhibition pattern could theoretically arise from blocking
NMDA receptors on interneurons with PCP, where an
increase in glutamate, instead, may act on Ca2 + -permeable
AMPA receptors to regulate NO release. Interestingly most
neurons that express this subtype of AMPA receptor and/or
produce NO are GABAergic interneurons (Gabbott and
Bacon, 1995; Jonas et al, 1994; Szabadits et al, 2007; Yan
et al, 1996; Yin et al, 1994).
The decrease in NO levels was most pronounced at a time
point (60–90 min) coinciding with the time for PPI
measurements following baclofen injection. Tentatively,
the temporal association between the effects of baclofen
on PPI and NO release gives further support to the
hypothesis that NO signaling in the medial PFC may be
partly responsible for the effects of baclofen on PPI.
Although the medium dose of baclofen (5 mg/kg) potently
decreased NO levels, this effect was completely absent for
the highest dose (10 mg/kg). This ‘inverted U’-like shape of
the dose response curve remains to be explained, but may
possibly reflect a more widespread engagement of GABAB
receptors in the brain, paralleled with the visibly decreased
basal activity at this dose, which is likely to be caused by the
muscle-relaxing and sedative effects of baclofen (Nevins
et al, 1993). Additionally, GABAB receptors are coupled to G
proteins, Ca2 + channels, K + channels, and adenylyl cyclase,
and are situated both presynaptically as auto- or hetero-
receptors and at postsynaptic neurons. Thus, these recep-
tors are capable of modulating release of various
neurotransmitters as well as hyperpolarizing the postsy-
naptic membrane potential (for review see Bettler et al,
2004; Couve et al, 2000) and this complexity should call for
caution when interpreting the above-mentioned results.
Concluding Remarks
This study demonstrates that signaling through GABAB
receptors mediates certain effects of PCP on information
processing and that the PFC is strongly implicated in these
effects. Furthermore, an interaction between GABAB and
NO signaling was detected as evidenced by converging
effects of these pathways on PPI and on prefrontal NO
release in vivo. Baclofen had an effect on PPI per se
following systemic, but not prefrontal injections, tentatively
indicating that GABAB receptors in the PFC are involved in
the effects of PCP but not in the modulation of baseline PPI.
Taken together, the present findings support recent
hypotheses on compromised inhibition following adminis-
tration of NMDA receptor antagonists leading to a
disinhibition of the PFC (Tanaka, 2008; Zhang et al,
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2008). Interestingly, activation of the hippocampus and PFC
in patients with schizophrenia has been demonstrated in
some, but not all, studies of cerebral blood flow (Catafau
et al, 1994; Friston et al, 1992; Ingvar and Franzen, 1974;
Malaspina et al, 2004; Taylor et al, 2007). The recent finding
that the mGlu2/3 receptor agonist LY2140023 significantly
improves positive and negative symptoms in schizophrenia
(Patil et al, 2007), also points in the direction of
disinhibition, as the most likely effect of this compound is
to reduce glutamate signaling in the brain. This study
proposes a role for GABAB receptor signaling in the effects
of PCP, possibly with altered NO levels as a downstream
mediator. These results expand the recent finding that
prefrontal NO/sGC signaling is important for the effects of
PCP (Fejgin et al, 2008) and provide behavioral and
biochemical support for NO as an effector of a disinhibited
PFC. Future studies of the glutamate/GABAB/NO signaling
pathway may bring greater insight into the mechanisms
underlying cortical disinhibition in relation to disrupted
information processing, and thus their putative importance
for cognitive deficits in schizophrenia.
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